Track Madrigal Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Madrigal Pharmaceuticals, Inc. MDGL · Stock Open Madrigal Pharmaceuticals, Inc. in new tab

427.39 USD
EPS
-5.85
P/B
16.00
ROE
-24.82
Beta
-1.00
Target Price
688.94 USD
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc.

🧾 Earnings Recap – Q1 2026

The stock gained 6.4% post-earnings, reflecting investor approval of strong net sales growth driven by accelerating Rezdiffra adoption and a rapidly expanding addressable market in MASH.

  • Q1 2026 net sales reached $311 million, up 127% year-over-year.
  • Active Rezdiffra patients grew to over 42,250, a 2.5x increase from Q1 2025.
  • The U.S. diagnosed MASH market expanded nearly 50% since 2023, now estimated at 460,000 patients.
  • Rezdiffra penetration remains below 10%, underscoring significant runway ahead.
  • Management highlighted a robust data generation strategy with upcoming presentations reinforcing efficacy and cardiovascular risk benefits.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 18, 2027
EPS-5.85
Book Value27.00
Price to Book16.00
Debt/Equity56.50
% Insiders5.795%
Growth
Revenue Growth0.50%
Estimates
Forward P/E38.54
Forward EPS11.21
Target Mean Price688.94

DCF valuation

Model fair value for Madrigal Pharmaceuticals, Inc. (MDGL)
Result
Sign in to run the valuation for MDGL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
18 analysts · consensus Strong buy · mean target 688.94 USD (low 479.00, high 962.00) · as of 12 Nov 2026
Low 479.00
Mean 688.94
High 962.00
Price 427.39
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Madrigal Pharmaceuticals, Inc. Logo Madrigal Pharmaceuticals, Inc. Analysis (MDGL)

United States Health Care Official Website Stock

Is Madrigal Pharmaceuticals, Inc. a good investment? Madrigal Pharmaceuticals, Inc. (MDGL) is currently trading at 427.39 USD. Market analysts have a consensus price target of 688.94 USD. This suggests a potential upside from current levels.

Earnings Schedule: Madrigal Pharmaceuticals, Inc. is expected to release its next earnings report on Feb. 18, 2027. The market consensus estimate for Forward EPS is 11.21.

Investor FAQ

Does Madrigal Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Madrigal Pharmaceuticals, Inc.?

Madrigal Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 18, 2027. The company currently has a trailing EPS of -5.85.

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Exchange Ticker
FRA (Germany) YDO1.F
LSE (United Kingdom) 0JXI.L
NMS (United States) MDGL
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 25, 2016 0.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion